Skip to main content

Table 3 Subset of significant predictors of period 2 DAS28 remission

From: The effect of deep or sustained remission on maintenance of remission after dose reduction or withdrawal of etanercept in patients with rheumatoid arthritis

End of period 1 predictor Odds ratio (95% CI) P value
SJC28 = 0 vs > 0 2.1 (1.4, 3.0) < 0.001
TJC28 = 0 vs > 0 1.7 (1.2, 2.5) 0.003
Study 0.008
 PRESERVE vs T2T 0.7 (0.4, 1.2)  
 PRIZE vs T2T 1.7 (0.8, 3.5)  
Sustained deep remission vs not sustained remission 2.4 (1.5, 3.9) < 0.001
ESR ≤ ULN vs > ULN 2.7 (1.5, 4.8) 0.001
Treatment < 0.001
 ETN 25 mg + MTX vs PBO + MTX 2.7 (1.7, 4.3)  
 ETN 50 mg + MTX vs PBO + MTX 3.3 (2.1, 5.0)  
 MTX vs PBO 0.7 (0.3, 1.7)  
  1. The subset of significant predictors was determined using a stepwise model with the following “end of period 1” predictors: sustained deep remission vs not; age in 10-year units; gender; body mass index ≤ 18.5, > 18.5 to ≤ 30, 30; HAQ ≤ 0.5 vs > 0.5; ESR ≤ ULN vs > ULN; SJC28 = 0 vs > 0; TJC28 = 0 vs > 0; study; treatment group
  2. CI confidence interval, ESR erythrocyte sedimentation rate, ETN etanercept, HAQ health assessment questionnaire, MTX methotrexate, PBO placebo, SJC28 swollen joint count measured using 28 joints, TJC28 tender joint count measured using 28 joints, ULN upper limit of normal